{"id":"https://openalex.org/W2575178171","doi":"https://doi.org/10.1080/13696998.2017.1285780","title":"Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer","display_name":"Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer","publication_year":2017,"publication_date":"2017-01-20","ids":{"openalex":"https://openalex.org/W2575178171","doi":"https://doi.org/10.1080/13696998.2017.1285780","mag":"2575178171","pmid":"https://pubmed.ncbi.nlm.nih.gov/28107090"},"language":"en","primary_location":{"id":"doi:10.1080/13696998.2017.1285780","doi":"https://doi.org/10.1080/13696998.2017.1285780","is_oa":true,"landing_page_url":"https://doi.org/10.1080/13696998.2017.1285780","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/13696998.2017.1285780?needAccess=true&role=button","source":{"id":"https://openalex.org/S155267287","display_name":"Journal of Medical Economics","issn_l":"1369-6998","issn":["1369-6998","1941-837X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320449","host_organization_name":"Informa","host_organization_lineage":["https://openalex.org/P4310320449"],"host_organization_lineage_names":["Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medical Economics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://www.tandfonline.com/doi/pdf/10.1080/13696998.2017.1285780?needAccess=true&role=button","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5085058149","display_name":"Fernando Rivera","orcid":"https://orcid.org/0000-0001-8915-226X","observed_orcids":["https://orcid.org/0000-0001-8915-226X","https://orcid.org/0000-0003-4962-3949","https://orcid.org/0000-0002-7185-0534"]},"institutions":[{"id":"https://openalex.org/I4210099858","display_name":"Marqu\u00e9s de Valdecilla University Hospital","ror":"https://ror.org/01w4yqf75","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210099858"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Fernando Rivera","raw_affiliation_strings":["Hospital Universitario Marqu\u00e9s de Valdecilla, Santander, Spain;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital Universitario Marqu\u00e9s de Valdecilla, Santander, Spain;","institution_ids":["https://openalex.org/I4210099858"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112485010","display_name":"Manuel Valladares","orcid":"https://orcid.org/0009-0007-2301-3719","observed_orcids":["https://orcid.org/0009-0007-2301-3719"]},"institutions":[{"id":"https://openalex.org/I4210153139","display_name":"Hospital Universitario Virgen del Roc\u00edo","ror":"https://ror.org/04vfhnm78","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210153139"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Manuel Valladares","raw_affiliation_strings":["Hospital Universitario Virgen del Roc\u00edo, Sevilla, Spain;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital Universitario Virgen del Roc\u00edo, Sevilla, Spain;","institution_ids":["https://openalex.org/I4210153139"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007638405","display_name":"Salvador Gea","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Salvador Gea","raw_affiliation_strings":["Unidad de Farmacoeconom\u00eda e Investigaci\u00f3n de Resultados en Salud, AMGEN, S.A., Barcelona, Spain;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Unidad de Farmacoeconom\u00eda e Investigaci\u00f3n de Resultados en Salud, AMGEN, S.A., Barcelona, Spain;","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5090182282","display_name":"Noem\u00ed L\u00f3pez-Mart\u00ednez","orcid":"https://orcid.org/0000-0001-9339-3883","observed_orcids":["https://orcid.org/0000-0001-9339-3883"]},"institutions":[{"id":"https://openalex.org/I4210107926","display_name":"Oblikue Consulting (Spain)","ror":"https://ror.org/01ksntm04","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210107926"]}],"countries":["ES"],"is_corresponding":true,"raw_author_name":"Noem\u00ed L\u00f3pez-Mart\u00ednez","raw_affiliation_strings":["Oblikue Consulting S.L., Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oblikue Consulting S.L., Barcelona, Spain","institution_ids":["https://openalex.org/I4210107926"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5090182282"],"corresponding_institution_ids":["https://openalex.org/I4210107926"],"apc_list":null,"apc_paid":null,"fwci":3.2206,"has_fulltext":true,"cited_by_count":11,"citation_normalized_percentile":{"value":0.92102641,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":96},"biblio":{"volume":"20","issue":"6","first_page":"574","last_page":"584"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9063000082969666,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9063000082969666,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.08869999647140503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.0019000000320374966,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.9070000052452087},{"id":"https://openalex.org/keywords/panitumumab","display_name":"panitumumab","score":0.9340000152587891},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.968999981880188},{"id":"https://openalex.org/keywords/mfolfox6","display_name":"mFOLFOX6","score":0.9490000009536743},{"id":"https://openalex.org/keywords/metastatic-colorectal-cancer","display_name":"metastatic colorectal cancer","score":0.9539999961853027},{"id":"https://openalex.org/keywords/ras-wild-type","display_name":"RAS wild-type","score":0.984000027179718},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.9240000247955322},{"id":"https://openalex.org/keywords/semi-markov-model","display_name":"semi-Markov model","score":0.8870000243186951},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.8420000076293945},{"id":"https://openalex.org/keywords/spanish-national-health-system","display_name":"Spanish National Health System","score":0.6510000228881836},{"id":"https://openalex.org/keywords/direct-costs","display_name":"direct costs","score":0.3799999952316284}],"concepts":[{"id":"https://openalex.org/C2778332735","wikidata":"https://www.wikidata.org/wiki/Q417775","display_name":"Panitumumab","level":5,"score":0.940994143486023},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.8873071670532227},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.886035680770874},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5793104767799377},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.5645453929901123},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.528608500957489},{"id":"https://openalex.org/C3017976582","wikidata":"https://www.wikidata.org/wiki/Q179661","display_name":"First line treatment","level":3,"score":0.4337530732154846},{"id":"https://openalex.org/C2781187634","wikidata":"https://www.wikidata.org/wiki/Q20969980","display_name":"KRAS","level":4,"score":0.3131803274154663},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.23588567972183228},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.15328148007392883}],"mesh":[{"descriptor_ui":"D000068258","descriptor_name":"Bevacizumab","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D000068258","descriptor_name":"Bevacizumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000077544","descriptor_name":"Panitumumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002955","descriptor_name":"Leucovorin","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D002955","descriptor_name":"Leucovorin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005472","descriptor_name":"Fluorouracil","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D005472","descriptor_name":"Fluorouracil","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008390","descriptor_name":"Markov Chains","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009944","descriptor_name":"Organoplatinum Compounds","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D009944","descriptor_name":"Organoplatinum Compounds","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D013030","descriptor_name":"Spain","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018631","descriptor_name":"ras Proteins","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019057","descriptor_name":"Quality-Adjusted Life Years","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1080/13696998.2017.1285780","doi":"https://doi.org/10.1080/13696998.2017.1285780","is_oa":true,"landing_page_url":"https://doi.org/10.1080/13696998.2017.1285780","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/13696998.2017.1285780?needAccess=true&role=button","source":{"id":"https://openalex.org/S155267287","display_name":"Journal of Medical Economics","issn_l":"1369-6998","issn":["1369-6998","1941-837X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320449","host_organization_name":"Informa","host_organization_lineage":["https://openalex.org/P4310320449"],"host_organization_lineage_names":["Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medical Economics","raw_type":"journal-article"},{"id":"pmid:28107090","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28107090","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of medical economics","raw_type":"Clinical Trial, Phase II"}],"best_oa_location":{"id":"doi:10.1080/13696998.2017.1285780","doi":"https://doi.org/10.1080/13696998.2017.1285780","is_oa":true,"landing_page_url":"https://doi.org/10.1080/13696998.2017.1285780","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/13696998.2017.1285780?needAccess=true&role=button","source":{"id":"https://openalex.org/S155267287","display_name":"Journal of Medical Economics","issn_l":"1369-6998","issn":["1369-6998","1941-837X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320449","host_organization_name":"Informa","host_organization_lineage":["https://openalex.org/P4310320449"],"host_organization_lineage_names":["Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medical Economics","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307105","display_name":"Amgen","ror":"https://ror.org/03g03ge92"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2575178171.pdf","grobid_xml":"https://content.openalex.org/works/W2575178171.grobid-xml"},"referenced_works_count":49,"referenced_works":["https://openalex.org/W861557199","https://openalex.org/W1187844298","https://openalex.org/W1458753240","https://openalex.org/W1845370611","https://openalex.org/W1870988441","https://openalex.org/W1967628954","https://openalex.org/W1973267502","https://openalex.org/W1978324722","https://openalex.org/W1994222210","https://openalex.org/W2004997290","https://openalex.org/W2006022204","https://openalex.org/W2008460730","https://openalex.org/W2010344947","https://openalex.org/W2015287759","https://openalex.org/W2015714921","https://openalex.org/W2017314771","https://openalex.org/W2025029039","https://openalex.org/W2030499271","https://openalex.org/W2045916016","https://openalex.org/W2065434214","https://openalex.org/W2066040529","https://openalex.org/W2066390717","https://openalex.org/W2085633477","https://openalex.org/W2086021499","https://openalex.org/W2089315574","https://openalex.org/W2098227097","https://openalex.org/W2103789431","https://openalex.org/W2106787323","https://openalex.org/W2108235590","https://openalex.org/W2123965006","https://openalex.org/W2125447919","https://openalex.org/W2136466711","https://openalex.org/W2140510616","https://openalex.org/W2140741940","https://openalex.org/W2141479869","https://openalex.org/W2152912304","https://openalex.org/W2155173005","https://openalex.org/W2155840608","https://openalex.org/W2164620659","https://openalex.org/W2314901090","https://openalex.org/W2342626985","https://openalex.org/W2470575266","https://openalex.org/W2484437366","https://openalex.org/W2597591782","https://openalex.org/W2917837889","https://openalex.org/W3143265745","https://openalex.org/W3151241602","https://openalex.org/W3193088544","https://openalex.org/W4285719527"],"related_works":["https://openalex.org/W2045916016","https://openalex.org/W6902346864","https://openalex.org/W1187844298","https://openalex.org/W2095953274","https://openalex.org/W2149122513","https://openalex.org/W2402621086","https://openalex.org/W2314901090","https://openalex.org/W2342626985","https://openalex.org/W2891256468","https://openalex.org/W2394925869"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"assess":[2,187],"the":[3,42,92,108,114,120,125,131,161,188,191,196,218,228,243,263,272,284,287,311],"cost-effectiveness":[4],"of":[5,24,64,82,118,122,127,135,190,203,286,293],"panitumumab":[6,148,204,296],"in":[7,17,33,208,213],"combination":[8,18,209],"with":[9,19,26,51,58,210,295,306],"mFOLFOX6":[10,20,211,298,309],"(oxaliplatin,":[11],"5-fluorouracil,":[12],"and":[13,75,77,87,116,130,133,153,180,227,250,278],"leucovorin)":[14],"vs":[15,205],"bevacizumab":[16,307],"as":[21],"first-line":[22,212,291],"treatment":[23,292],"patients":[25],"wild-type":[27,214],"RAS":[28,215],"metastatic":[29],"colorectal":[30],"cancer":[31],"(mCRC)":[32],"Spain.":[34],"METHODS:":[35],"A":[36,172],"semi-Markov":[37],"model":[38,244,260],"was":[39,158,175,225,237,245,255],"developed":[40],"including":[41,168],"following":[43],"health":[44,102],"states:":[45],"Progression":[46],"free;":[47],"Progressive":[48,55,71],"disease:":[49,56,72],"Treat":[50,57],"best":[52],"supportive":[53],"care;":[54],"subsequent":[59,123],"active":[60],"therapy;":[61],"Attempted":[62],"resection":[63,74],"metastases;":[65],"Disease":[66],"free":[67,85],"after":[68,73],"metastases":[69],"resection;":[70],"relapse;":[76],"Death.":[78],"Parametric":[79],"survival":[80,86,89],"analyses":[81,179,183,241],"patient-level":[83,145],"progression":[84],"overall":[88],"data":[90,106,146],"from":[91,107,144,147,160],"PEAK":[93,109,197,273],"Phase":[94,274],"II":[95,275],"clinical":[96,276],"trial":[97,110,277],"were":[98,111,142,184],"used":[99],"to":[100,137,186,247],"estimate":[101],"state":[103],"transitions.":[104],"Additional":[105],"considered":[112,301],"for":[113,310],"dose":[115],"duration":[117],"therapy,":[119,124],"use":[121],"occurrence":[126],"adverse":[128],"events,":[129],"incidence":[132],"probability":[134],"time":[136],"metastasis":[138],"resection.":[139],"Utility":[140],"weightings":[141],"calculated":[143],"trials":[149],"evaluating":[150],"first-,":[151],"second-,":[152],"third-line":[154],"treatments.":[155],"The":[156,239,253],"study":[157],"performed":[159,185],"Spanish":[162,282,312],"National":[163],"Health":[164],"System":[165],"(NHS)":[166],"perspective":[167],"only":[169],"direct":[170],"costs.":[171],"life-time":[173],"horizon":[174],"applied.":[176],"Probabilistic":[177],"sensitivity":[178,182,240],"scenario":[181],"robustness":[189],"model.":[192],"RESULTS:":[193],"Based":[194,270],"on":[195,257,271],"trial,":[198],"which":[199],"demonstrated":[200],"greater":[201],"efficacy":[202],"bevacizumab,":[206],"both":[207],"mCRC":[216,294],"patients,":[217],"estimated":[219,229],"incremental":[220,230],"cost":[221,231],"per":[222,232],"life-year":[223],"gained":[224,236],"\u20ac16,567":[226],"quality-adjusted":[233],"life":[234],"year":[235],"\u20ac22,794.":[238],"showed":[242,289],"robust":[246],"alternative":[248],"parameters":[249],"assumptions.":[251],"LIMITATIONS:":[252],"analysis":[254,288],"based":[256],"a":[258,302],"simulation":[259],"and,":[261],"therefore,":[262],"results":[264,285],"should":[265],"be":[266,300],"interpreted":[267],"cautiously.":[268],"CONCLUSIONS:":[269],"taking":[279],"into":[280],"account":[281],"costs,":[283],"that":[290],"+":[297,308],"could":[299],"cost-effective":[303],"option":[304],"compared":[305],"NHS.":[313]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2023,"cited_by_count":2},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2017-01-26T00:00:00"}